欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01477 欧康维视生物-B

休市中 08-07 16:08:13

5.295

+0.230

+4.54%

最高5.350	最低5.070	成交量67.95万
今开5.070	昨收5.065	日振幅5.53%
总市值43.15亿	流通市值43.15亿	总股本8.15亿
成交额355.18万	换手率0.08%	流通股本8.15亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01477","market":"HK","secType":"STK","nameCN":"欧康维视生物-B","latestPrice":5.295,"timestamp":1786090093003,"preClose":5.065,"halted":0,"volume":679500,"delay":0,"changeRate":0.04540967423494561,"floatShares":815000000,"shares":815000000,"eps":-0.23265274106379474,"marketStatus":"休市中","change":0.23,"latestTime":"08-07 16:08:13","open":5.07,"high":5.35,"low":5.07,"amount":3551815,"amplitude":0.055281,"askPrice":5.305,"askSize":1500,"bidPrice":5.22,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-0.23350541335979352,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786325400000},"marketStatusCode":7,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":5.065,"openAndCloseTimeList":[[1786066200000,1786075200000],[1786078800000,1786089600000]],"volumeRatio":2.0640947743348326,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01477","defaultTab":"news","newsList":[{"id":"2658673625","title":"每周股票复盘：泽璟制药（688266）首次半年度盈利6.4亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2658673625","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658673625?lang=zh_cn&edition=full","pubTime":"2026-08-09 01:21","pubTimestamp":1786209669,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，泽璟制药报收于121.7元，较上周的122.1元下跌0.33%。本周，泽璟制药8月7日盘中最高价报122.0元。本周关注点来自业绩披露要点：公司自成立以来首次实现半年度盈利，归母净利润为64,001.11万元。机构调研要点2026年上半年，公司实现营业收入120,537.96万元，同比增长220.88%，主要因确认技术授权收入66,230.95万元及商业化产品销售增长；归母净利润达64,001.11万元，首次实现半年度盈利。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900000148.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","01477","BK0239","BK1574","688266"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657625992","title":"泽璟制药获得发明专利授权：“氘代2-芳杂环-3-氧-2,3-二氢哒嗪-4-甲酰胺类抑制剂及其制备方法和应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2657625992","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657625992?lang=zh_cn&edition=full","pubTime":"2026-08-08 03:38","pubTimestamp":1786131538,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示泽璟制药新获得一项发明专利授权，专利名为“氘代2-芳杂环-3-氧-2,3-二氢哒嗪-4-甲酰胺类抑制剂及其制备方法和应用”，专利申请号为CN202011367513.8，授权日为2026年8月7日。今年以来泽璟制药新获得专利授权4个，较去年同期增加了100%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080800003726.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","BK1574","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657644613","title":"汇宇制药（688553）披露控股股东部分股份质押公告，8月7日股价上涨7.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657644613","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657644613?lang=zh_cn&edition=full","pubTime":"2026-08-07 22:22","pubTimestamp":1786112575,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，汇宇制药报收于11.91元，较前一交易日上涨7.59%，最新总市值为74.54亿元。近日，汇宇制药披露《关于控股股东、实际控制人部分股份质押的公告》。公告显示，公司控股股东、实际控制人丁兆先生持有公司股份168,818,814股，占公司总股本的26.97%。本次质押7,500,000股，占其所持股份的4.44%，占公司总股本的1.20%。本次质押后，丁兆先生累计质押股份为7,500,000股，无股份被用作重大资产重组或业绩补偿担保，亦不存在潜在业绩补偿义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700041125.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1191","01477","BK0239","688553"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657148526","title":"中邮证券：首次覆盖泽璟制药给予买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2657148526","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657148526?lang=zh_cn&edition=full","pubTime":"2026-08-07 17:48","pubTimestamp":1786096123,"startTime":"0","endTime":"0","summary":"中邮证券有限责任公司盛丽华,陈灿近期对泽璟制药进行研究并发布了研究报告《商业化产品快速放量，研发全面开花》，首次覆盖泽璟制药给予买入评级。公司商业化产品矩阵处于放量期，在研双/多抗临床数据优势明显，首次覆盖，给予“买入”评级。最新盈利预测明细如下：该股最近90天内共有7家机构给出评级，买入评级7家；过去90天内机构目标均价为141.08。本文数据来源于中邮证券有限责任公司，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700030922.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657616355","title":"8月7日泽璟制药涨8.45%，汇添富创新医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2657616355","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657616355?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:41","pubTimestamp":1786092082,"startTime":"0","endTime":"0","summary":"证券之星消息，8月7日泽璟制药涨8.45%，收盘报121.7元，换手率3.44%，成交量9.11万手，成交额10.75亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共110家，其中持有数量最多的公募基金为汇添富基金的汇添富创新医药混合A。汇添富创新医药混合A目前规模为89.62亿元，最新净值1.7141，较上一交易日上涨1.23%，近一年下跌15.27%。汇添富创新医药混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700028017.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","159938","BK1191","01477","BK1161","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657516695","title":"港股异动 | AI制药商业化兑现能力逐步凸显 剂泰科技-P(07666.HK)大涨超7%领跑","url":"https://stock-news.laohu8.com/highlight/detail?id=2657516695","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657516695?lang=zh_cn&edition=full","pubTime":"2026-08-07 11:51","pubTimestamp":1786074686,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","07666","01477","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657521991","title":"股市必读：浙江震元新发布《关于为子公司震元制药提供担保的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657521991","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657521991?lang=zh_cn&edition=full","pubTime":"2026-08-06 01:37","pubTimestamp":1785951430,"startTime":"0","endTime":"0","summary":"公司公告汇总：浙江震元为全资子公司震元制药提供最高额30,000万元连带责任保证，担保期限五年，截至公告日实际担保额度71,000万元，占公司2025年经审计净资产的35.95%。公司公告汇总关于为子公司震元制药提供担保的进展公告2026年8月3日，浙江震元与中信银行绍兴分行签署《最高额保证合同》，为全资子公司震元制药在2026年8月3日至2031年8月3日期间向中信银行申请的最高额30,000万元人民币贷款提供连带责任保证。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600001536.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","000705","01477","BK0250","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657454762","title":"开源证券：给予泽璟制药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2657454762","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657454762?lang=zh_cn&edition=full","pubTime":"2026-08-05 21:00","pubTimestamp":1785934844,"startTime":"0","endTime":"0","summary":"开源证券股份有限公司余汝意,聂媛媛近期对泽璟制药进行研究并发布了研究报告《公司信息更新报告：2026H1-ZG006海外授权兑现价值，加速全球化》，给予泽璟制药买入评级。最新盈利预测明细如下：该股最近90天内共有7家机构给出评级，买入评级7家；过去90天内机构目标均价为141.08。本文数据来源于开源证券股份有限公司，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500041651.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657471745","title":"九洲药业：近年来公司新增承接3家全球头部跨国制药企业的项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2657471745","media":"证券日报 ","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657471745?lang=zh_cn&edition=full","pubTime":"2026-08-05 20:17","pubTimestamp":1785932220,"startTime":"0","endTime":"0","summary":"证券日报网8月5日讯 ，九洲药业在接受调研时表示，公司持续深化与核心战略客户的合作，巩固存量业务基础。公司与部分全球大型制药企业建立了长期稳定的合作关系，除持续供应成熟商业化项目外，每年还承接多个不同阶段的创新药项目。国内市场方面，公司持续为多家头部创新药企业提供CDMO服务，合作逐步向临床后期及商业化阶段延伸。新客户拓展方面，公司持续推进全球大型制药企业及优质Biotech公司开发。近年来，公司新增承接3家全球头部跨国制药企业的项目，并持续深化与其他海外大型制药企业的合作；同时，国内创新药客户数量持续增加，临床中后期项目不断导入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-05/doc-inimhpmz5094040.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-05/doc-inimhpmz5094040.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["603456","01477","BK1191","BK0239","BK1574","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116586616","title":"欧康维视生物-B更新2026年7月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1116586616","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116586616?lang=zh_cn&edition=full","pubTime":"2026-08-05 17:02","pubTimestamp":1785920533,"startTime":"0","endTime":"0","summary":"欧康维视生物-B于2026年8月5日发布截至2026年7月31日的证券变动月报。公告显示，公司本月在法定股本、已发行股份及库存股份方面均保持平稳，股本总数未发生变化。根据2018年5月23日采纳的员工购股权计划，本月底计入13,317,816份未行使的期权，与上月保持一致。2021年购股权计划方面，本月内有27,402份期权已失效，期末结存45,297,500份。截至本月月末，公司整体股本结构仍维持稳定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656552449","title":"浙江震元（000705）披露为子公司震元制药提供3亿元担保进展，8月4日股价上涨0.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656552449","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656552449?lang=zh_cn&edition=full","pubTime":"2026-08-04 22:37","pubTimestamp":1785854236,"startTime":"0","endTime":"0","summary":"截至2026年8月4日收盘，浙江震元报收于6.67元，较前一交易日上涨0.15%，最新总市值为22.29亿元。近日，浙江震元发布《关于为子公司震元制药提供担保的进展公告》。公告显示，2026年8月3日，浙江震元与中信银行绍兴分行签署《最高额保证合同》，为全资子公司震元制药在2026年8月3日至2031年8月3日期间向中信银行申请的最高额30,000万元人民币贷款提供连带责任保证。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400041667.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01477","BK0250","BK1574","BK1191","000705"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656587458","title":"【券商聚焦】东吴证券维持歌礼制药（01672）买入评级 指核心管线获双重催化","url":"https://stock-news.laohu8.com/highlight/detail?id=2656587458","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656587458?lang=zh_cn&edition=full","pubTime":"2026-08-04 14:11","pubTimestamp":1785823914,"startTime":"0","endTime":"0","summary":"金吾财讯 | 东吴证券发布研报指，歌礼制药-B 核心品种ASC30已获美国FDA的III期临床批准，正式启动全球III期临床项目。核心管线进入注册临床关键阶段与后端创新管线数据亮眼，构成双重催化。此外，公司截至2025年年报的现金及现金等价物达14.4亿元人民币，为ASC30的III期临床推进提供了坚实的资金保障。东吴证券维持对歌礼制药2026至2028年营业收入预测，分别为0.46亿元、0.87亿元和1.36亿元人民币，维持“买入”评级。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987432","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672","601555","01477","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656589606","title":"歌礼制药-B早盘涨逾5% GLP-1口服小分子ASC30启动全球III期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2656589606","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656589606?lang=zh_cn&edition=full","pubTime":"2026-08-04 10:55","pubTimestamp":1785812100,"startTime":"0","endTime":"0","summary":"8月3日，歌礼制药宣布，每日一次口服小分子GLP-1已获得美国食品药品监督管理局的III期临床研究批准。ASC30是歌礼口服小分子肥胖症治疗管线组合中的核心支柱。公司已针对ASC30长期体重管理适应症启动了一项全球III期临床项目，将在美国、欧洲和加拿大开展两项关键临床试验，将入组约4，600名肥胖或超重受试者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-04/doc-inimchzv2245265.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","JDOC","III","BK1161","BK4144","BK1574","01477","BK4590","BK4134","GLP","BK1191","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656586300","title":"港股异动 | 歌礼制药-B(01672.HK)涨超6% GLP-1口服小分子ASC30启动全球III期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2656586300","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656586300?lang=zh_cn&edition=full","pubTime":"2026-08-04 09:42","pubTimestamp":1785807757,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01672","BK1515","BK1191","BK1161","BK1574","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656585371","title":"住友制药、住友化学股价下跌 此前做空机构发布报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2656585371","media":"环球市场播报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656585371?lang=zh_cn&edition=full","pubTime":"2026-08-04 09:09","pubTimestamp":1785805740,"startTime":"0","endTime":"0","summary":"美国空头机构哥谭城研究（Gotham City Research）针对两家日本企业发布报告后，住友制药与住友化学东京盘中股价均至少下跌 4.2%。住友化学发言人拒绝对该报告置评，住友制药发言人暂未予以回应。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-08-04/doc-inimcatv5518940.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","01477","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656037383","title":"歌礼制药-B(01672.HK)宣布其GLP-1口服小分子ASC30启动全球III期临床研究并公布其同类首创口服小分子GLP-1/GIP╱胰淀素固定剂量复方制剂的积极临床前数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2656037383","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656037383?lang=zh_cn&edition=full","pubTime":"2026-08-03 18:53","pubTimestamp":1785754428,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1191","01477","BK1515","BK1574","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656329804","title":"泽璟制药跌12% 华泰证券今日刚维持买入评级就跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2656329804","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656329804?lang=zh_cn&edition=full","pubTime":"2026-08-03 15:34","pubTimestamp":1785742445,"startTime":"0","endTime":"0","summary":"中国经济网北京8月3日讯 泽璟制药(688266.SH)今日收报107.42元，跌幅12.02%。\r\n\r\n　　华泰证券股份有限公司今日发布研报《泽璟制药(688266)：商业化与ZG005数据读出齐头并进》，研究员为代雯、李奕玮、唐庆雷。研报称，看好后续1L宫颈癌和神经内分泌癌2期数据读出，并预期年内启动多项3期临床，维持“买入”评级。\r\n\r\n　　(责任编辑：田云绯)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260803/32324574.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656348097","title":"股市必读：汇宇制药新发布《自愿披露参与全国药品集中采购拟中选的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2656348097","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656348097?lang=zh_cn&edition=full","pubTime":"2026-08-03 02:06","pubTimestamp":1785693976,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘，汇宇制药报收于10.45元，上涨4.6%，换手率2.65%，成交量13.45万手，成交额1.39亿元。公司公告汇总：汇宇制药3个产品拟中选第十二批全国药品集中采购，采购周期至2029年12月31日。交易信息汇总资金流向7月31日主力资金净流出473.91万元，占总成交额3.4%；游资资金净流入943.65万元，占总成交额6.77%；散户资金净流出469.75万元，占总成交额3.37%。上述产品在中标前已分别实现销售收入3518.44万元、133.24万元和24.64万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300000828.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01477","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656312404","title":"汇宇制药：3个产品拟中标第十二批全国药品集中采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2656312404","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656312404?lang=zh_cn&edition=full","pubTime":"2026-08-02 15:49","pubTimestamp":1785656970,"startTime":"0","endTime":"0","summary":"汇宇制药(688553.SH)公告称，公司参与第十二批全国药品集中采购，注射用盐酸表柔比星、注射用替考拉宁、亚叶酸钙注射液3个产品拟中标。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200005326.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","BK1574","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656311586","title":"泽璟制药（688266）2026年中报简析：营收净利润同比双双增长，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2656311586","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656311586?lang=zh_cn&edition=full","pubTime":"2026-08-02 06:01","pubTimestamp":1785621676,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期泽璟制药发布2026年中报。截至本报告期末，公司营业总收入12.05亿元，同比上升220.88%，归母净利润6.4亿元，同比上升979.09%。本报告期泽璟制药盈利能力上升，毛利率同比增幅5.55%，净利率同比增幅363.94%。持有泽璟制药最多的基金为汇添富创新医药混合A，目前规模为89.62亿元，最新净值1.6913，较上一交易日上涨0.21%，近一年下跌15.46%。本文数据来源于泽璟制药2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200001246.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","01477"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ocumension.com","stockEarnings":[{"period":"1week","weight":0.0464},{"period":"1month","weight":0.0828},{"period":"3month","weight":-0.2436},{"period":"6month","weight":-0.2425},{"period":"1year","weight":-0.4923},{"period":"ytd","weight":-0.2845}],"compareEarnings":[{"period":"1week","weight":-0.0084},{"period":"1month","weight":0.0607},{"period":"3month","weight":-0.0275},{"period":"6month","weight":-0.0336},{"period":"1year","weight":0.0234},{"period":"ytd","weight":0.0015}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"欧康维视生物是一家主要从事眼科药物的研发和商业化的公司。该公司产品主要包括OT-401“优施莹”氟轻松玻璃体内植入剂、OT-702“博优景”阿柏西普眼内注射溶液、OT-402“维速达尔”注射用维替泊芬、OT-204“欧沁”玻璃酸钠滴眼液及OT-305“贝特舒”盐酸倍他洛尔滴眼液等。该公司产品主要用于治疗葡萄膜炎、眼底疾病、屈光矫正、干眼症（DED）、青光眼及角结膜炎等各种眼前及眼后段疾病。该公司主要在中国国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.097698},{"month":2,"riseRate":0.5,"avgChangeRate":-0.037557},{"month":3,"riseRate":0.5,"avgChangeRate":0.044668},{"month":4,"riseRate":0.5,"avgChangeRate":0.015642},{"month":5,"riseRate":0.5,"avgChangeRate":0.087204},{"month":6,"riseRate":0.666667,"avgChangeRate":0.062947},{"month":7,"riseRate":0.5,"avgChangeRate":-0.003589},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.048988},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.082685},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.121217},{"month":11,"riseRate":0.333333,"avgChangeRate":0.004503},{"month":12,"riseRate":0.5,"avgChangeRate":0.058088}],"exchange":"SEHK","name":"欧康维视生物-B","nameEN":"OCUMENSION-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"欧康维视生物-B,01477,欧康维视生物-B股票,欧康维视生物-B股票老虎,欧康维视生物-B股票老虎国际,欧康维视生物-B行情,欧康维视生物-B股票行情,欧康维视生物-B股价,欧康维视生物-B股市,欧康维视生物-B股票价格,欧康维视生物-B股票交易,欧康维视生物-B股票购买,欧康维视生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}